Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2002 Oct;19(10):470-6.
doi: 10.1023/a:1020358419073.

A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI

Affiliations
Clinical Trial

A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI

Eric H M Hoomans et al. J Assist Reprod Genet. 2002 Oct.

Abstract

Purpose: To compare the efficacy, efficacy and safety of a fixed daily dose of recombinant FSH (Puregon) of a 100- and 200-IU regimen in Asian women undergoing ovarian stimulation for IVF/ICSI.

Methods: This was a prospective, randomized, double-blind, multicenter (n = 9) study. Prior to the start of rFSH, all women were pretreated with a gonadotropin releasing hormone agonist (GnRH-a) for pituitary downregulation.

Results: A total of 330 women were treated with rFSH: 163 subjects with 100 IU and 167 subjects with 200 IU. In the 200 IU treatment group, significantly more oocytes were retrieved compared to the 100 IU group (9.6 vs. 5.0 oocytes, p < 0.001). The total dose rFSH needed to develop at least three follicles with a diameter of >17 mm was significantly lower in the 100 IU treatment group (1,194 vs. 2,034 IU, p < 0.001). Although more cycle cancellations were seen in the 100 IU group (24 vs. 13%), the ongoing pregnancy rate per started cycle was comparable between both groups (16.6% in the 100 IU group vs. 15.0% in the 200 IU group).

Conclusions: The use of a 100 IU fixed dose is less effective in terms of the number of oocytes retrieved and the higher cancellation rate, but more efficient as indicated by a lower total recombinant FSH dose needed.

PubMed Disclaimer

References

    1. Out HJ, Mannaerts BMJL, Driessen SG, Coelingh Bennink HJ. A prospective, randomized, assessor-blind, multicenter study comparing recombinant follicle-stimulating hormone (Puregon vs Metrodin) in in-vitro fertilization. Hum Reprod. 1995;10:2534–2540. - PubMed
    1. Devroey P, Tournaye H, van Steirteghem A, Hendrix P, Out HJ. The use of a 100 IU starting dose of recombinant follicle stimulating hormone (Puregon) in in-vitro fertilization. Hum Reprod. 1998;13:565–566. - PubMed
    1. Out HJ, Lindenberg S, Mikkelsen AL, Eldar-Geva T, Healy DL, Leader A, Rodriguez-Escudero FJ, Garcia-Velasco J. P. A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation. Hum Reprod. 1999;14:622–627. - PubMed
    1. Out HJ, David I, Ron-El R, Friedler S, Shalev E, Geslevich J, Dor J, Shulman A, Ben-Rafael Z, Fisch B, Dirnfeld M. A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles. Hum Reprod. 2001;16:1104–1109. - PubMed
    1. CPMP Working Party on Efficacy of Medicinal Products: Good Clinical Practice for trials on medicinal products in the European Community. Pharmacol Toxicol. 1990;67:361–372. - PubMed

MeSH terms